µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to apply a novel advanced magnetic resonance imaging methodology
to evaluate the response to drug intervention involving two treatment arms of postmenopausal
participants with osteoporosis, randomized into either a teriparatide (Forteo™) or zoledronic
acid (Reclast™) group.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Eli Lilly and Company National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Novartis Pharmaceuticals